このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
AstraZeneca Pharma India マネジメント
マネジメント 基準チェック /14
現在、CEO に関する十分な情報がありません。
主要情報
Sanjeev Panchal
最高経営責任者
₹38.7m
報酬総額
| CEO給与比率 | 83.4% |
| CEO在任期間 | 1.6yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.1yrs |
| 取締役会の平均在任期間 | 1.6yrs |
経営陣の近況
Recent updates
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability
Jun 03
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S
May 22We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease
Apr 04Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Nov 10AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00
Jul 06Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?
Jun 16Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
Aug 02Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock
Feb 25Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Feb 04Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Jan 18
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years
Dec 31We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability
Dec 13Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching
Nov 25Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay
Nov 07What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?
Oct 20AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Sep 24If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today
Aug 28What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?
Aug 02Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?
Jul 12CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | ₹39m | ₹32m | ₹2b |
| Dec 31 2023 | n/a | n/a | ₹1b |
| Sep 30 2023 | n/a | n/a | ₹2b |
| Jun 30 2023 | n/a | n/a | ₹1b |
| Mar 31 2023 | ₹21m | ₹5m | ₹993m |
報酬と市場: Sanjeevの 総報酬 ($USD 463.46K ) は、 Indian市場 ($USD 476.98K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Sanjeevの報酬は過去 1 年間で 20% 以上増加しました。
CEO（最高経営責任者
Sanjeev Panchal (47 yo)
1.6yrs
在職期間
₹38,725,314
報酬
Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| MD, Country President & Director | 1.6yrs | ₹38.73m | データなし | |
| Whole-Time Director & CFO | less than a year | ₹30.59m | データなし | |
| Legal Counsel | 7.5yrs | ₹3.73m | データなし | |
| Company Secretary & Compliance Officer | 2yrs | データなし | データなし | |
| Vice President of Human Resources | no data | ₹12.28m | データなし | |
| Interim Business Unit Head of Oncology & Director of Commercial Excellence | 1.1yrs | データなし | データなし | |
| Head of Oncology Business Unit | less than a year | データなし | データなし | |
| Business Unit Head - Rare Disease unit | less than a year | データなし | データなし | |
| Legal Head | no data | データなし | データなし |
1.1yrs
平均在職期間
経験豊富な経営陣: ASTRAZENの経営陣は 経験豊富 とはみなされません ( 1.2年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| MD, Country President & Director | 1.6yrs | ₹38.73m | データなし | |
| Whole-Time Director & CFO | less than a year | ₹30.59m | データなし | |
| Independent Non-Executive Director | 7.7yrs | ₹1.20m | データなし | |
| Independent Chairman of the Board | 11.7yrs | ₹1.60m | データなし | |
| Additional Non-Executive Director | less than a year | データなし | データなし | |
| Independent Non-Executive Director | 2.7yrs | ₹1.30m | データなし | |
| Non-Executive Director | less than a year | データなし | データなし |
1.6yrs
平均在職期間
58yo
平均年齢
経験豊富なボード: ASTRAZENの 取締役会 は 経験豊富 ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。